Ammol.org

Ammol is a biotechnology company focused on developing innovative therapies for the treatment of hyperammonemia and related metabolic disorders. The company's primary focus is on the development of novel small molecule agents designed to lower systemic ammonia levels, which is critical for patients suffering from urea cycle disorders and hepatic encephalopathy. By targeting the underlying biochemical pathways of ammonia production and clearance, Ammol aims to provide more effective and manageable treatment options for these life-threatening conditions. The company is currently in the pre-clinical stage of development, advancing its lead candidates through rigorous testing to establish safety and efficacy profiles.